Physician profile
Paul C Chan
NPI 1386630879
$3,292.70
in general payments reported to CMS, 2019-2025
27 companies · $260 in 2025
The $260 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $687 · 2021: $669 · 2022: $711 · 2023: $223 · 2024: $188 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $581.25 | 2019-2021 | |
| Boston Scientific Corporation | $325.06 | 2019-2025 | Spaceoar Vue System - 10ml, Lithovue, Varithena Administration Pack |
| Abbvie INC. | $239.11 | 2021-2024 | Botox |
| Endo Pharmaceuticals INC. | $239.03 | 2019-2021 | |
| Urovant Sciences INC | $187.39 | 2021-2022 | |
| C. R. Bard, INC. & Subsidiaries | $185.58 | 2020-2021 | |
| Myovant Sciences INC. | $157.81 | 2021-2022 | |
| Blue Earth Diagnostics | $156.98 | 2020-2023 | |
| Axonics, INC. | $142.00 | 2022-2024 | Bulkamid |
| Dendreon Pharmaceuticals LLC | $138.64 | 2019-2022 | |
| Pfizer INC. | $136.07 | 2019-2020 | |
| Janssen Biotech, INC. | $130.41 | 2020-2025 | Erleada |
| Sumitomo Pharma America, INC. | $116.63 | 2023-2025 | Orgovyx, Gemtesa |
| Olympus America INC. | $113.12 | 2024-2025 | Itind System |
| Coloplast Corp | $83.30 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $48.36 | 2020 | |
| Innovation Technologies INC | $48.20 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.71 | 2019-2021 | |
| Clarus Therapeutics INC. | $35.17 | 2021 | |
| Genzyme Corporation | $33.66 | 2019-2022 | |
| Urogen Pharma, INC. | $26.67 | 2022 | |
| Civco Medical Instruments | $25.44 | 2024 | |
| 180 Medical, INC. | $25.00 | 2019 | |
| Allergan, INC. | $24.42 | 2019 | |
| Acerus Pharmaceuticals Corporation | $16.80 | 2022 | |
| Myriad Genetic Laboratories, INC. | $15.66 | 2022 | |
| Mission Pharmacal Company | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.